FOLD Q4 2024 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$150M+30.1% YoY

Gross Profit

$135M90.1% margin

Operating Income

$16M10.7% margin

Net Income

$15M9.8% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$785M

Total Liabilities

$591M

Stockholders' Equity

$194M

Cash & Equivalents

$214M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$150M	$115M	+30.1%
Gross Profit	$135M	$104M	+30.0%
Operating Income	$16M	-$4M	+532.6%
Net Income	$15M	-$34M	+143.6%

Geographic Segments

Non-US

$124M60%

UNITED STATES

$82M40%